Navigation Links
Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for Characterization of Protein Biomarkers Associated With Neurological Conditions
Date:4/20/2009

CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Xennex Inc. (Xennex) announced today that it is collaborating with Satoris Inc. (Satoris) and has provided Satoris with access to GeneCards(R) and associated proprietary tools, including GeneAlaCart and early access to input from the advanced prototype of GeneCards(R) version 3.0, which is in advanced stages of development. Satoris is utilizing GeneCards and the related technology for research related to its identification and characterization of protein biomarkers associated with neurological disease such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy to create new diagnostic tools for earlier, better healthcare decisions.

"We welcome the opportunity to collaborate with Xennex and utilize the newest available GeneCards tools in the further characterization of plasma protein biomarkers we have identified in our studies as being significant in neurodegenerative disease process," said Cris McReynolds, President & CEO of Satoris.

Dr. David Warshawsky, President & CEO of Xennex, stated: "We are very pleased that we can offer Satoris with our most advanced tools and the latest GeneCards developments to assist in their work. Satoris' work is of great potential for improved diagnosis and treatment of devastating conditions and we are delighted that GeneCards is assisting in this important cutting-edge research."

About GeneCards(R)

GeneCards(R) (http://www.genecards.org) is a searchable, integrated database of human genes that provides concise genomic, proteomic, transcriptomic, genetic and functional information on all known and predicted human genes. Information featured in GeneCards includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs & compounds and direct links to cutting-edge research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel.

About Xennex

Founded in 2003, Xennex Inc. (http://www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services.

Xennex' customers include many of the world's leading Biotech and Pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe.

About Satoris

Founded in 2003 and based in Redwood City, California, Satoris, Inc. is a molecular diagnostics company focused on developing blood-based tests for Alzheimer's disease. For more information, see http://www.satorisinc.com.

    For further information, please contact:

    Xennex Inc.
    David Warshawsky, Ph.D.
    Chief Executive Officer
    Tel: +1 617 497 7774
    davidw@xennexinc.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Xennex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.
2. Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies
3. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
6. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
7. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
8. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
9. Care to Care Begins Providing Radiology Benefit Management Services to Touchstone Health
10. Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market
11. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... MA (PRWEB) , ... March 30, 2017 , ... ... companies as a host of the Massachusetts Technology Leadership Council’s NewCo festival on ... and thought leaders share their knowledge from the inside. , DrugDev – ...
(Date:3/30/2017)... 2017 Personal Genome Diagnostics Inc. (PGDx) today announced ... Association for Cancer Research (AACR) Annual Meeting 2017, being held ... The company also announced that five scientists associated with PGDx—two ... Annual AACR Team Science Award. ... Doug Ward , CEO ...
(Date:3/29/2017)... OF PRUSSIA, Pa. , March 29, 2017 /PRNewswire/ ... to care, which is why CSL Behring awards Local ... work of rare disease patient groups. These groups tackle ... voices are heard on Capitol Hill and in statehouses ... funding cycle, the community-based grant was awarded to New ...
(Date:3/29/2017)... YORK , March 29, 2017 "Surging ... programs deployed by the government are expected to drive ... The gesture recognition market is expected to ... a CAGR of 29.63% between 2017 and 2022. The ... 15.27 billion by 2022, growing at a CAGR of ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):